Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE.
DIURIL vs ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing sodium, chloride, and water excretion, and reducing peripheral vascular resistance.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
Oral: Initially enalapril 5 mg and HCTZ 12.5 mg once daily; titrate to maximum enalapril 20 mg / HCTZ 25 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Enalaprilat: terminal 11 hours (multiple doses), prolonged in renal impairment (creatinine clearance <30 mL/min: 30-40 h). Hydrochlorothiazide: terminal 6-15 hours (mean 10 h), prolonged in renal impairment.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Enalapril: renal 60-80% (40-60% as enalaprilat, 20-40% as metabolites); fecal 20-40%. Hydrochlorothiazide: renal 95% (unchanged).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic